PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
Healthcare
$0.92 +1.21%
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
52W Low $0.51High $1.67
Volume 5.25M
Average 1.04M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$27.75B
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$12.77B
FY 2025 · Annual
+63176.2% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5B) |
| Depreciation & Amortization | 5.36K | 86 | 17.36K | 21.11K | 1.55B |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.11M | 5.2M | 7.61M | 6.85M | 4.11B |
| Change in Working Capital | 75.82K | 4.47M | (199.28K) | (5.75M) | (382.97K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (105.82K) | (90.12K) | 5.76M | (5.3M) | 1.89M |
| Other Working Capital | 181.64K | 4.57M | (5.96M) | (453.77K) | (2.27M) |
| Other Non-Cash Items | 241.03K | 5.47M | 1.87M | 1.46M | 1.08B |
| Operating Cash Flow | (12.49M) | (25.71M) | (33.64M) | (35.03M) | (27.75B) |
| Capital Expenditures | 0 | 0 | 0 | (29K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (29K) | 0 |
| Debt Repayment | 0 | 25M | (59.3K) | (3.18M) | (7.56M) |
| Common Stock Issued | 48.54M | 9.86M | 16.13M | 22.6M | 20.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 344.13K | (568.87K) | 308.94K | 774.09K | 12.76B |
| Financing Cash Flow | 48.89M | 34.29M | 16.38M | 20.19M | 12.77B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 36.4M | 8.58M | (17.26M) | (14.87M) | (14.98B) |
| Free Cash Flow | (12.49M) | (25.71M) | (33.64M) | (35.06M) | (27.75B) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$34.5B
+ D&A$1.6B
+ Stock-Based Comp$4.1B
+ Deferred Tax$0
- Working Capital-$383.0K
+ Other Non-Cash$1.1B
= Operating Cash Flow-$27.8B
- Capex$0
= Free Cash Flow-$27.8B
Analysis
FY2025 free cash flow is -$27.8B. FCF conversion is 80.5% of net income. Operating cash flow was -$27.8B, with capex of $0. The largest bridge item is Stock-Based Comp at $4.1B.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 21, 2026 | |
| 8-K | Current report | Oct 21, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 21, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 20, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 |
Does PDSB generate free cash flow?
PDS Biotechnology Corporation (PDSB) generated -$27.75B of free cash flow in fiscal 2025.
How much operating cash flow does PDSB produce?
Operating cash flow was -$27.75B, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.